Edotreotide Archives

Tag: Edotreotide

The octreotide derivative edotreotide labeled with gallium 68 (Ga-68) with potential application in somatostatin receptor (SSTR) imaging in conjunction with positron emission tomography (PET). Similar to octreotide, gallium Ga 68-edotreotide binds to SSTRs, especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells and their metastases, thereby allowing for imaging of SSTR-expressing cells upon PET. Gallium Ga 68-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelating the substituted octreotide to Ga-68 via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA).

29 Jan 2025

By Ronny Allan

4 Comments

Clinical Trial of PRRT ITM11 177Lu-Edotreotide – COMPETE for GEPNETs: Awaiting approval for GEPNETs (COMPETE) expected 28th Aug 2026

Clinical Trials and Research68Ga edotreotide (TOCscan®), Advanced neuroendocrine cancer, Afinitor, COMPETE trial, Edotreotide, EndolucinBeta, Everolimus, Gastro-entero-pancreatic neuroendocrine tumour (GEP-NET), Neuroendocrine cancer, Neuroendocrine tumour (NET), No-Carrier-Added Lutetium-177 (n.c.a. Lu177), Octreotide, Solucin ®, Somatostatin analogues, Somatostatin receptors (SSTR), TOCscan®

Update 4th July 2026. Data from the Phase 3 COMPETE trial - ITM11 [177Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival. Efficacy and harms results support the use of [177Lu]Lu-edotreotide in early lines of therapy in patients with advanced, progressive GEP NETs. Bonus info about other trials for NET: 1. There is also an ITM11 product on trial for more aggressive G2/G3 GEPNETs known as COMPOSE - click here 2. An ITM11 product trial for Lung and Thymic NETs is running and currently in Phase 3 - known as LEVEL - Click here 3. A ITM11…

18 Jan 2017

By Ronny Allan

5 Comments

Theranostics for Neuroendocrine Cancer – A Find and Destroy Mission

Awareness, Clinical Trials and Research, Living with Neuroendocrine Cancer, TreatmentAdvanced neuroendocrine cancer, Edotreotide, Ga68 PET/CT, Indium 111-pentetreotide, Lutathera, Metastatic Neuroendocrine Cancer, NETSPOT, NETTER-1, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Nuclear medicine, Octreoscan (Octreotide scan), Octreotide, Pancreatic NET (PanNET), Paraganglioma, Pentetreotide, Peptide receptor radionuclide therapy (PRRT), Pheochromocytoma, PRRT, Radionuclide, Satoreotide (Lutetium-177), SomaKit TOC

Theranostics is a joining of the words therapeutics and diagnostics. You may also see it conveyed as 'Theragnostics' and these terms are interchangeable. The basic aim of theranotistics is to find and then destroy the 'bad guys'. With Neuroendocrine Cancer, finding the tumours (the bad guys) can often be a challenge - they can be small and/or difficult to find - they are sometimes expert at camouflage. Moreover, once found, they can then be difficult to treat (destroy), as they can often prove resistant to conventional cancer drugs and many are inoperable due to sheer quantity, spread and positioning. When…